Pacific Biosciences downgraded by JP Morgan
$PACB
Biotechnology: Laboratory Analytical Instruments
Industrials
JP Morgan downgraded Pacific Biosciences from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | Buy → Neutral | UBS | |
| 6/3/2024 | $4.00 | Buy | Jefferies |
| 4/22/2024 | Overweight → Neutral | JP Morgan | |
| 4/18/2024 | $7.00 → $2.50 | Buy → Neutral | Goldman |
| 12/14/2023 | $11.00 | Overweight | Stephens |
| 12/14/2023 | Neutral | Guggenheim | |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 11/17/2023 | $13.00 → $10.00 | Neutral → Buy | UBS |
144 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)
8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)
8-K/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)
UBS downgraded Pacific Biosciences from Buy to Neutral
Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00
JP Morgan downgraded Pacific Biosciences from Overweight to Neutral
SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)
SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)
SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in
MENLO PARK, Calif., Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023. "I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry, President and Chief Executive Officer. "His deep understanding of genomics and broad experience in technological innovation in the field has made him a valuable leader as PacB
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the
Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year decline of 33% and 23%, respectively. "Though challenging, 2024 was a productive year for PacBio as we launched groundbreaking products, strengthened our balance sheet, and made significant pr
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clini
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering 400,000 shares of PacBio common stock, and restricted stock units ("RSUs") covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance wi
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera